CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS

Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating cancers treatable by inhibition of WRN, including cancers charac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GRAYBILL, Todd L, JONES, Brian T, YING, Maben, ADAMS, Ashley, GLOGOWSKI, Michal Pawel, GODFREY, Nicole, PHELAN, James P, TAYGERLY, Joshua P.G, JESO, Valer, DEMARTINO, Michael P, RIDGERS, Lance Howard, SHENJE, Raynold, BURGESS, Joelle Lorraine, MANNS, Sharada, DOWDELL, Sarah E, TALLANT, Matthew, SHEARER, Barry George, BURY, Michael J, MURPHY, Dennis, NEVINS, Neysa
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same. L'invention concerne certains dérivés succinamido de Formule (I) : (I) qui inhibent l'enzyme hélicase ATP-dépendante du syndrome de Wemer (WRN), en particulier inhibent l'activité du domaine hélicase WRN et sont utiles dans le traitement de cancers pouvant être traités par inhibition de WRN, y compris des cancers caractérisés par une instabilité des microsatellites (MSI) et/ou un système de réparation des mésappariements ADN défectueux (dMMR). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés d'utilisation de tels composés, et des procédés de fabrication de ceux-ci.